Navigation Links
Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting

Diversity of Abstracts Reflects Continued Growth of Eisai's Commitment to Oncology

WOODCLIFF LAKE, N.J., May 31, 2007 /PRNewswire/ -- Eisai announced today that several abstracts covering clinical data about their oncology pipeline compounds have been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting. ASCO takes place in Chicago from June 1-5, 2007.

These abstracts reveal a growing and diverse oncology clinical development program at Eisai. In addition to the variety of oncology product classes under investigation, these compounds are being studied in advanced diseases where there remains considerable unmet medical need, particularly in refractory metastatic breast cancer, advanced non-small cell lung cancer, and advanced ovarian cancer.

The following abstracts highlight data from pipeline compounds that have been accepted for presentation at this year's ASCO meeting.


    Product        Abstract Details                        Location Details


    Eribulin       Phase II Study of Eribulin Mesylate     June 2, 2007 8:00

    Mesylate       (E7389) Halichondrin B Analog in        AM - 1:00 PM

    (E7389)        Patients with Refractory Breast Cancer  Location: S403

    Abstract No:   Poster Number: 21

    1034



    Eribulin       Phase II Study of Eribulin Mesylate     June 2, 2007 8:00

    Mesylate       (E7389), a Mechanistically Novel        AM - 1:00 PM

    (E7389)        Inhibitor of Microtubule Dynamics,      Location: E451a

    Abstract No:   in Patients with Advanced Non-Small

    7546           Cell Lung Cancer (nsclc)

                   Poster Number: 20



    MORAb-003      Novel Phase II Study Design of          June 2, 2007

    Abstract No:   MORAb-003, a Monoclonal Antibody        2:00 PM - 6:00 PM

    5583           against Folate Receptor Alpha in        Location: S Hall A2

                   Platinum-Sensitive Ovarian Cancer

                   in First Relapse

    
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:9/22/2014)... , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... and fiscal 2014 ended July 31, 2014 on Monday, September ... to discuss the results at 11:00 AM ET. Participating in ... Andrew A. Krakauer , President and CEO; Jorgen ... A. Sheldon , Senior Vice President, CFO and Treasurer; and ...
(Date:9/22/2014)... , Sept. 22, 2014  Inovio Pharmaceuticals, Inc. ... has initiated a phase I clinical trial in ... the safety, tolerability, and immunogenicity of INO-3106. This ... causes most aerodigestive cancers. Aerodigestive cancers ... cords, and parts of the esophagus and windpipe. ...
(Date:9/22/2014)... , Sept. 22, 2014  Seres Health, a clinical-stage ... the human microbiome, today announced that it has been ... Fierce 15 biotechnology companies, designating it as one of ... "Amid a great deal of ain,t-it-cool ... focus and commitment to practical therapeutic development," says ...
Breaking Medicine Technology:Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Seres Health Named a "Fierce 15" Biotech Company for 2014 2
... Jan. 4, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: ... company focused on cardiac and vascular surgery, announced today ... the position of Vice President, Research and Development; and ... Vice President, Market Development Surgical Adhesives and Starch Medical ...
... /PRNewswire-Asia/ -- The 2011 Medical Korea Awards ceremony was ... the awards ceremony, 10 outstanding medical tourism service providers ... medical tourism agencies, designated as ,first movers, in the ... Yonsei Severance Hospital (General Director: Park Yong-won) won this ...
Cached Medicine Technology:CryoLife Enhances Management Team with Promotions 2CryoLife Enhances Management Team with Promotions 3CryoLife Enhances Management Team with Promotions 4CryoLife Enhances Management Team with Promotions 5Medical Korea Offers 2011 Awards to Top Medical Tourism Service Providers (Institutions) 2
(Date:9/22/2014)... Oaks, CA (PRWEB) September 22, 2014 ... now offering a special offer for Invisalign. Invisalign is ... smiles and correct bite problems. Typical pricing can vary ... and the number of aligners that are needed. During ... for just $4,495. , About a fifth of the ...
(Date:9/22/2014)... The invitation only Summit held on ... industry executives and thought leaders from major fitness ... Fitness, and Xsport Fitness. Also in attendance were ... agencies and private equity investors representing over 1,500 ... The Summit highlighted best practices for solving new ...
(Date:9/22/2014)... -- New research raises doubts about the possible benefits ... cancer who used e-cigarettes along with traditional cigarettes were ... the devices, a Memorial Sloan Kettering study found. These ... likely -- to have quit smoking than patients who ... Sept. 22 in Cancer , involved almost 1,100 ...
(Date:9/22/2014)... 2014 At the 10th Clinton ... Nutrition Partnership (SNP) announced the successful launch of ... Cardiovascular Risk Reduction Program for Women. The announcement ... mitigate their risk of heart disease through a ... plan for addressing significant global challenges made by ...
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 Tristar ... American icon Jack LaLanne, best known as the 'Godfather ... "ANYTHING IS POSSIBLE" premiering September 24th at the ... documentary gives an inspiring insight behind the man whose ... benefits of fitness and nutrition. The name of the ...
Breaking Medicine News(10 mins):Health News:Thousand Oaks Cosmetic Dentist, Sharon Shamoiel DDS, Is Now Offering a Special on Invisalign 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 3Health News:E-Cigarettes Don't Help Cancer Patients Quit Smoking: Study 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:Tristar Products Premieres The Jack LaLanne Documentary at TriBeCa Film Center in New York City 2Health News:Tristar Products Premieres The Jack LaLanne Documentary at TriBeCa Film Center in New York City 3
... to directly measure the brain,s temperature without inserting a probe ... get the brain,s precise temperature with a device the diameter ... to findings presented May 1 at the annual meeting of ... first time that anyone has presented data on the brain ...
... Johns Hopkins have shown in laboratory experiments in mice ... inside the heart,s muscle cells blunts the most serious ... These include heart muscle enlargement, scar tissue formation ... Specifically, the Johns Hopkins team found that their intervention ...
... -- Children born to women exposed to bisphenol A (BPA) ... to experience wheezing early in life, according to a new ... many hard plastic food containers, water bottles and the lining ... in more than 90 percent of the U.S. population, the ...
... News) -- A new study finds that different patterns of ... arterial stiffness, which is associated with cardiovascular disease. Stiff ... and are also associated with a buildup of plaque in ... to a heart attack. In this study, Dr. Danny ...
... reserve" in early-onset Alzheimer,s disease (AD) and PET-CT examinations ... patients. "Although early-onset Alzheimer,s dementia is quite ... carry the diagnosis," said Dr. Jacob Richard Hodge, lead ... Rochester, Minn. "Symptoms are often unexpected and support networks ...
... have discovered a link between low levels of vitamin D ... May 1 at the annual meeting of the Pediatric Academic ... play an important role in anemia. Anemia, which occurs ... is diagnosed and tracked by measuring hemoglobin levels. Symptoms of ...
Cached Medicine News:Health News:Researchers develop device to measures brain temperature non-invasively 2Health News:Animal studies reveal new route to treating heart disease 2Health News:Animal studies reveal new route to treating heart disease 3Health News:Mom's Exposure to Plastics Chemical Tied to Baby's Wheeze 2Health News:PET-CT exams help identify cognitive reserve in early-onset Alzheimer's disease 2Health News:Low vitamin D in kids may play a role in anemia 2
A simple solution to hand assisted laparoscopic surgery....
GelPort hand access laparoscopy combines the patient outcomes of minimally invasive surgery with the speed and precision of open surgery....
... HandPort Systems non-adhesive sealing method ... Laparoscopic Surgrery (HALS) procedures, allowing ... and palpate throughout. Because HALS ... 6 cm, patients experience less ...
The CPAP TREND 110 delivers performance with quiet operation. Can be used together with the SomnoPlus CPAP Mask and AquaTrend Heated Humidifier....
Medicine Products: